Wedbush reaffirmed their outperform rating on shares of Pharvaris (NASDAQ:PHVS - Free Report) in a report released on Thursday,Benzinga reports. Wedbush currently has a $27.00 price target on the stock.
Separately, Cantor Fitzgerald dropped their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th.
Read Our Latest Analysis on Pharvaris
Pharvaris Price Performance
Shares of NASDAQ PHVS traded down $0.57 during trading hours on Thursday, reaching $16.05. The stock had a trading volume of 81,019 shares, compared to its average volume of 74,972. The company has a market cap of $839.25 million, a price-to-earnings ratio of -5.73 and a beta of -2.86. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The business's fifty day moving average is $15.52 and its two-hundred day moving average is $17.13.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Sell-side analysts forecast that Pharvaris will post -2.71 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of PHVS. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Pharvaris in the fourth quarter valued at about $64,000. KLP Kapitalforvaltning AS bought a new stake in Pharvaris during the fourth quarter worth about $111,000. Point72 Asset Management L.P. acquired a new stake in shares of Pharvaris during the fourth quarter worth approximately $152,000. Finally, Legal & General Group Plc increased its holdings in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares in the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
